Status:
WITHDRAWN
Topical Bimatoprost Solution 0.03%in Stable Vitiligo
Lead Sponsor:
Gian Sagar Medical College and Hospital
Conditions:
Vitiligo
Repigmentation
Eligibility:
All Genders
10-40 years
Phase:
PHASE4
Brief Summary
Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors,...
Detailed Description
Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Vitiligo does not cause physical symptoms but because of its unsightly appearanc...
Eligibility Criteria
Inclusion
- Patient of either sex and at least 10 years old
- Have a diagnosis of vitiligo with no news lesions or growth of old lesions in the past 6 months
- Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form
- Agree to follow and undergo all study-related procedures
Exclusion
- Patients showing evidence of spontaneous repigmentation in any of the lesions
- Patients with rapidly progressive disease were also excluded.
- Patients with hypersensitivity to the drug or any of its constituents
- Patients with BSA \> 5%
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01202513
Start Date
August 1 2010
End Date
November 1 2010
Last Update
August 3 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.